EVOLUS, INC. Weighted Average Number of Shares Outstanding, Basic and Diluted
EVOLUS, INC. (EOLS) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 33.74 million shares for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-25.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2021-03-25
- EVOLUS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-12-31 was 33.75M shares, a 9.79% increase year-over-year.
- EVOLUS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-09-30 was 33.75M shares, a 22.85% increase year-over-year.
- EVOLUS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-06-30 was 33.73M shares, a 23.07% increase year-over-year.
- EVOLUS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2020-03-31 was 33.72M shares, a 23.38% increase year-over-year.
- EVOLUS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2020 was 33.74M shares, a 19.48% increase from fiscal 2019.
- EVOLUS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2019 was 28.24M shares, a 15.72% increase from fiscal 2018.
- EVOLUS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2018 was 24.40M shares, a 47.65% increase from fiscal 2017.
- EVOLUS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2017 was 16.53M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2020-12-31 | 33.75M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | 33.75M shares derived: average of 2 quarters · filed 2021-03-25 | 33.74M shares derived: average of 3 quarters · filed 2021-03-25 | 33.74M shares 10-K · filed 2021-03-25 |
| 2020-09-30 | 33.75M shares 10-Q · filed 2020-10-29 | 33.74M shares derived: average of 2 quarters · filed 2020-10-29 | 33.73M shares 10-Q · filed 2020-10-29 | 32.99M shares derived: average of 4 quarters · filed 2021-03-25 |
| 2020-06-30 | 33.73M shares 10-Q · filed 2020-08-10 | 33.73M shares 10-Q · filed 2020-08-10 | 32.73M shares derived: average of 3 quarters · filed 2021-03-25 | 31.42M shares derived: average of 4 quarters · filed 2021-03-25 |
| 2020-03-31 | 33.72M shares 10-Q · filed 2020-05-11 | 32.23M shares derived: average of 2 quarters · filed 2021-03-25 | 30.64M shares derived: average of 3 quarters · filed 2021-03-25 | 29.83M shares derived: average of 4 quarters · filed 2021-03-25 |
| 2019-12-31 | 30.74M shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | 29.11M shares derived: average of 2 quarters · filed 2021-03-25 | 28.54M shares derived: average of 3 quarters · filed 2021-03-25 | 28.24M shares 10-K · filed 2021-03-25 |
| 2019-09-30 | 27.47M shares 10-Q · filed 2020-10-29 | 27.44M shares derived: average of 2 quarters · filed 2020-10-29 | 27.40M shares 10-Q · filed 2020-10-29 | 27.39M shares derived: average of 4 quarters · filed 2020-10-29 |
| 2019-06-30 | 27.41M shares 10-Q · filed 2020-08-10 | 27.37M shares 10-Q · filed 2020-08-10 | 27.37M shares derived: average of 3 quarters · filed 2020-08-10 | 26.72M shares derived: average of 4 quarters · filed 2020-08-10 |
| 2019-03-31 | 27.33M shares 10-Q · filed 2020-05-11 | 27.34M shares derived: average of 2 quarters · filed 2020-05-11 | 26.49M shares derived: average of 3 quarters · filed 2020-05-11 | 25.79M shares derived: average of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | 27.36M shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | 26.06M shares derived: average of 2 quarters · filed 2020-02-25 | 25.27M shares derived: average of 3 quarters · filed 2020-02-25 | 24.40M shares 10-K · filed 2020-02-25 |
| 2018-09-30 | 24.77M shares 10-Q · filed 2019-11-04 | 24.23M shares derived: average of 2 quarters · filed 2019-11-04 | 23.42M shares 10-Q · filed 2019-11-04 | 21.30M shares derived: average of 4 quarters · filed 2019-11-04 |
| 2018-06-30 | 23.69M shares 10-Q · filed 2019-08-12 | 21.96M shares 10-Q · filed 2019-08-12 | 20.15M shares derived: average of 3 quarters · filed 2019-08-12 | 19.24M shares derived: average of 4 quarters · filed 2019-08-12 |
| 2018-03-31 | 20.23M shares 10-Q · filed 2019-05-01 | 18.38M shares derived: average of 2 quarters · filed 2019-05-01 | 17.76M shares derived: average of 3 quarters · filed 2019-05-01 | 17.45M shares derived: average of 4 quarters · filed 2019-05-01 |
| 2017-12-31 | 16.53M shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-20 | 16.53M shares derived: average of 2 quarters · filed 2019-03-20 | 16.53M shares derived: average of 3 quarters · filed 2019-03-20 | 16.53M shares 10-K · filed 2019-03-20 |
| 2017-09-30 | 16.53M shares 10-Q · filed 2018-11-05 | 16.53M shares derived: average of 2 quarters · filed 2018-11-05 | 16.53M shares 10-Q · filed 2018-11-05 | |
| 2017-06-30 | 16.53M shares 10-Q · filed 2018-08-02 | 16.53M shares 10-Q · filed 2018-08-02 | ||
| 2017-03-31 | 16.53M shares 10-Q · filed 2018-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |